{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:49:51Z","timestamp":1791838191188,"version":"4.3.4"},"reference-count":76,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,4,18]],"date-time":"2016-04-18T00:00:00Z","timestamp":1460937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"funder":[{"name":"Agenus"},{"name":"Genocea"},{"name":"Vical"},{"DOI":"10.13039\/100005564","name":"Gilead","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"crossref"}]},{"name":"AiCuris"},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.vaccine.2016.03.111","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T06:43:23Z","timestamp":1461998603000},"page":"2939-2947","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":136,"title":["The global roadmap for advancing development of vaccines against sexually transmitted infections: Update and next steps"],"prefix":"10.1016","volume":"34","author":[{"given":"Sami L.","family":"Gottlieb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn D.","family":"Deal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte","family":"Giersing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Bolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Timms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Gray-Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann E.","family":"Jerse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline E.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasee S.","family":"Moorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Kiarie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Broutet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.03.111_bib0380","doi-asserted-by":"crossref","first-page":"e0143304","DOI":"10.1371\/journal.pone.0143304","article-title":"Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting","volume":"10","author":"Newman","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0385","doi-asserted-by":"crossref","first-page":"e114989","DOI":"10.1371\/journal.pone.0114989","article-title":"Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012","volume":"10","author":"Looker","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0390","doi-asserted-by":"crossref","first-page":"e0140765","DOI":"10.1371\/journal.pone.0140765","article-title":"Global and regional estimates of prevalent and incident herpes simplex virus type 1 infections in 2012","volume":"10","author":"Looker","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0395","doi-asserted-by":"crossref","first-page":"e1001396","DOI":"10.1371\/journal.pmed.1001396","article-title":"Global estimates of syphilis in pregnancy and associated adverse outcomes: analysis of multinational antenatal surveillance data","volume":"10","author":"Newman","year":"2013","journal-title":"PLOS Med"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0400","series-title":"GLOBOCAN: International Agency for Research on Cancer. Cervical cancer: estimated incidence, mortality and prevalence worldwide in 2012","year":"2012"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0405","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra1411426","article-title":"Pelvic inflammatory disease","volume":"372","author":"Brunham","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0410","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00007435-199207000-00001","article-title":"Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results","volume":"19","author":"Westrom","year":"1992","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0415","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.aids.0000198081.09337.a7","article-title":"Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies","volume":"20","author":"Freeman","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0420","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.vaccine.2013.07.087","article-title":"Toward global prevention of sexually transmitted infections (STIs): the need for STI vaccines","volume":"32","author":"Gottlieb","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0425","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/OLQ.0b013e31827bd637","article-title":"Screening and treating Chlamydia trachomatis genital infection to prevent pelvic inflammatory disease: interpretation of findings from randomized controlled trials","volume":"40","author":"Gottlieb","year":"2013","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0430","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.2012.205107","article-title":"Cephalosporin-resistant gonorrhea in North America","volume":"309","author":"Kirkcaldy","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0435","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(06)69482-8","article-title":"Global control of sexually transmitted infections","volume":"368","author":"Low","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0440","first-page":"1523","article-title":"Sexually transmitted infections: vaccine development for global health","volume":"32","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0445","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.vaccine.2014.01.053","article-title":"Vaccines against sexually transmitted infections: the way forward","volume":"32","author":"Broutet","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0450","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.vaccine.2013.08.032","article-title":"Current barriers, challenges and opportunities for the development of effective STI vaccines: point of view of vaccine producers, biotech companies and funding agencies","volume":"32","author":"Dodet","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0455","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"386","author":"Global Burden of Disease Study 2013 Collaborators","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0460","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","author":"GBD 2013 Mortality and Causes of Death Collaborators","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0465","doi-asserted-by":"crossref","first-page":"e1001778","DOI":"10.1371\/journal.pmed.1001778","article-title":"Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis","volume":"12","author":"Morrison","year":"2015","journal-title":"PLOS Med"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0470","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/OLQ.0b013e3181d3d023","article-title":"Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2","volume":"37","author":"Alsallaq","year":"2010","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0475","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.vaccine.2008.11.074","article-title":"Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa","volume":"27","author":"Freeman","year":"2009","journal-title":"Vaccine"},{"issue":"14","key":"10.1016\/j.vaccine.2016.03.111_bib0480","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.vaccine.2013.11.007","article-title":"The theoretical impact of vaccines that protect against sexually transmitted infections and disease","volume":"32","author":"Garnett","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0485","series-title":"Press release: The Bill & Melinda Gates Foundation to fund disease surveillance network in Africa and Asia to prevent childhood mortality and help prepare for the next epidemic","year":"2015"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0490","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3201\/eid2106.141270","article-title":"Cost-effectiveness of Chlamydia vaccination programs for young women","volume":"21","author":"Owusu-Edusei","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0495","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.vaccine.2014.01.052","article-title":"Summary and recommendations from a National Institute of Allergy and Infectious Diseases (NIAID) workshop on \u201cNext Generation Herpes Simplex Virus Vaccines\u201d","volume":"32","author":"Knipe","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0500","series-title":"WHO preferred product characteristics","author":"World Health Organization","year":"2014"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0505","series-title":"WHO preferred product characteristics (PPC) for malaria vaccines","author":"World Health Organization","year":"2014"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2015.12.076","article-title":"Status of vaccine research and development of vaccines for herpes simplex virus","author":"Johnston","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0515","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/QAD.0000000000000646","article-title":"Changes in the contribution of genital tract infections to HIV acquisition among Kenyan high-risk women from 1993 to 2012","volume":"29","author":"Masese","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0520","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1103151","article-title":"Efficacy results of a trial of a herpes simplex vaccine","volume":"366","author":"Belshe","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0525","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/cid\/cis891","article-title":"Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women","volume":"56","author":"Bernstein","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0530","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/infdis\/jit651","article-title":"Correlate of immune protection against HSV-1 genital disease in vaccinated women","volume":"209","author":"Belshe","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0535","doi-asserted-by":"crossref","first-page":"e0121518","DOI":"10.1371\/journal.pone.0121518","article-title":"Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs","volume":"10","author":"Bernard","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0540","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.vaccine.2005.08.088","article-title":"A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects","volume":"24","author":"de Bruyn","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0545","series-title":"HSV shedding: biomarker for disease severity and response to antivirals","author":"Agyemang","year":"2015"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0550","series-title":"53rd Interscience conference on antimicrobial agents and chemotherapy","article-title":"Novel therapeutic vaccine for genital herpes reduces genital HSV-2 shedding","author":"Wald","year":"2013"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0555","doi-asserted-by":"crossref","first-page":"e76407","DOI":"10.1371\/journal.pone.0076407","article-title":"A novel DNA vaccine technology conveying protection against a lethal herpes simplex viral challenge in mice","volume":"8","author":"Dutton","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0560","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.1016\/j.vaccine.2012.09.057","article-title":"A Vaxfectin\u00ae-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes","volume":"30","author":"Veselenak","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0565","doi-asserted-by":"crossref","first-page":"6427","DOI":"10.1128\/JVI.00416-15","article-title":"Genomic, phylogenetic, and recombinational characterization of herpes simplex virus 2 strains","volume":"89","author":"Kolb","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0570","doi-asserted-by":"crossref","first-page":"8219","DOI":"10.1128\/JVI.01303-15","article-title":"Genome sequencing and analysis of geographically diverse clinical isolates of herpes simplex virus 2","volume":"89","author":"Newman","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0575","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1128\/JVI.01987-13","article-title":"Evolution and diversity in human herpes simplex virus genomes","volume":"88","author":"Szpara","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0580","doi-asserted-by":"crossref","first-page":"8206","DOI":"10.1128\/JVI.01302-15","article-title":"Global diversity within and between human herpesvirus 1 and 2 glycoproteins","volume":"89","author":"Lamers","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0585","doi-asserted-by":"crossref","first-page":"9213","DOI":"10.1128\/JVI.01213-15","article-title":"Patient-specific neutralizing antibody responses to herpes simplex virus are attributed to epitopes on gD, gB, or both and can be type specific","volume":"89","author":"Cairns","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0590","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nature12110","article-title":"Immune surveillance by CD8\u03b1\u03b1+ skin-resident T cells in human herpes virus infection","volume":"497","author":"Zhu","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0595","doi-asserted-by":"crossref","first-page":"e1002258","DOI":"10.1371\/journal.ppat.1002258","article-title":"Development of a transformation system for Chlamydia trachomatis: restoration of glycogen biosynthesis by acquisition of a plasmid shuttle vector","volume":"7","author":"Wang","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0600","doi-asserted-by":"crossref","first-page":"e0124840","DOI":"10.1371\/journal.pone.0124840","article-title":"Plasmid-encoded Pgp5 is a significant contributor to Chlamydia muridarum induction of hydrosalpinx","volume":"10","author":"Huang","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0605","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.chom.2015.03.014","article-title":"Integrating chemical mutagenesis and whole-genome sequencing as a platform for forward and reverse genetic analysis of Chlamydia","volume":"17","author":"Kokes","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0610","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/978-1-4939-1261-2_20","article-title":"A chemical mutagenesis approach to identify virulence determinants in the obligate intracellular pathogen Chlamydia trachomatis","volume":"1197","author":"Nguyen","year":"2014","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0615","first-page":"e50636","article-title":"Forward genetic approaches in Chlamydia trachomatis","author":"Nguyen","year":"2013","journal-title":"J Vis Exp"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0620","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1128\/IAI.00353-15","article-title":"Intrauterine infection with plasmid-free Chlamydia muridarum reveals a critical role of the plasmid in chlamydial ascension and establishes a model for evaluating plasmid-independent pathogenicity","volume":"83","author":"Chen","year":"2015","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0625","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1084\/jem.20111266","article-title":"A live-attenuated chlamydial vaccine protects against trachoma in nonhuman primates","volume":"208","author":"Kari","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0630","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1128\/IAI.00841-15","article-title":"Comparable genital tract infection, pathology, and immunity in rhesus macaques inoculated with wild-type or plasmid-deficient Chlamydia trachomatis serovar D","volume":"83","author":"Qu","year":"2015","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0635","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/icb.2015.79","article-title":"A multi-subunit Chlamydia vaccine inducing neutralizing antibodies and strong IFN-gamma CMI responses protects against a genital infection in minipigs","volume":"94","author":"Boje","year":"2015","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0640","series-title":"Chlamydia vaccine research","author":"Statens Serum Institut","year":"2016"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0645","doi-asserted-by":"crossref","first-page":"aaa8205","DOI":"10.1126\/science.aaa8205","article-title":"VACCINES. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells","volume":"348","author":"Stary","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0650","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.1128\/IAI.67.11.5699-5708.1999","article-title":"Experimental gonococcal genital tract infection and opacity protein expression in estradiol-treated mice","volume":"67","author":"Jerse","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0655","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/mi.2012.12","article-title":"Neisseria gonorrhoeae selectively suppresses the development of Th1 and Th2 cells, and enhances Th17 cell responses, through TGF-beta-dependent mechanisms","volume":"5","author":"Liu","year":"2012","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0660","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/infdis\/jit354","article-title":"Enhancement of adaptive immunity to Neisseria gonorrhoeae by local intravaginal administration of microencapsulated IL-12","volume":"208","author":"Liu","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.03.111_bib1660","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/OLQ.0b013e31820ff9a4","article-title":"The natural history of incident gonococcal infection in adolescent women","volume":"38","author":"Stupiansky","year":"2011","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0665","doi-asserted-by":"crossref","first-page":"e806","DOI":"10.7717\/peerj.806","article-title":"Population structure of Neisseria gonorrhoeae based on whole genome data and its relationship with antibiotic resistance","volume":"3","author":"Ezewudo","year":"2015","journal-title":"PeerJ"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0670","doi-asserted-by":"crossref","first-page":"e0133982","DOI":"10.1371\/journal.pone.0133982","article-title":"The gonococcal transcriptome during infection of the lower genital tract in women","volume":"10","author":"McClure","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0675","doi-asserted-by":"crossref","first-page":"e00892","DOI":"10.1128\/mBio.00892-13","article-title":"Lipid A's structure mediates Neisseria gonorrhoeae fitness during experimental infection of mice and men","volume":"4","author":"Hobbs","year":"2013","journal-title":"MBio"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0680","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(15)00837-5","article-title":"Stillbirths: rates, risk factors, and acceleration towards 2030","author":"Lawn","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0685","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1155\/2015\/705720","article-title":"Social network investigation of a syphilis outbreak in Ottawa, Ontario","volume":"26","author":"D\u2019Angelo-Scott","year":"2015","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0690","doi-asserted-by":"crossref","first-page":"h3457","DOI":"10.1136\/bmj.h3457","article-title":"Syphilis and gonorrhoea increase sharply in England","volume":"350","author":"Mayor","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0695","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1071\/SH14153","article-title":"Increasing trends of syphilis among men who have sex with men in high income countries","volume":"12","author":"Read","year":"2015","journal-title":"Sex Health"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0700","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1084\/jem.189.4.647","article-title":"Treponema pallidum major sheath protein homologue Tpr K is a target of opsonic antibody and the protective immune response","volume":"189","author":"Centurion-Lara","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0705","doi-asserted-by":"crossref","first-page":"e2222","DOI":"10.1371\/journal.pntd.0002222","article-title":"Fine analysis of genetic diversity of the tpr gene family among treponemal species, subspecies and strains","volume":"7","author":"Centurion-Lara","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0710","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1128\/IAI.68.2.824-831.2000","article-title":"The tprK gene is heterogeneous among Treponema pallidum strains and has multiple alleles","volume":"68","author":"Centurion-Lara","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0715","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.4049\/jimmunol.0902788","article-title":"Antigenic variation in Treponema pallidum: TprK sequence diversity accumulates in response to immune pressure during experimental syphilis","volume":"184","author":"Giacani","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0720","doi-asserted-by":"crossref","first-page":"7485","DOI":"10.1128\/IAI.73.11.7485-7494.2005","article-title":"Defining the interaction of the Treponema pallidum adhesin Tp0751 with laminin","volume":"73","author":"Cameron","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0725","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1128\/IAI.01083-10","article-title":"Bifunctional role of the Treponema pallidum extracellular matrix binding adhesin Tp0751","volume":"79","author":"Houston","year":"2011","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0730","doi-asserted-by":"crossref","first-page":"e1002822","DOI":"10.1371\/journal.ppat.1002822","article-title":"Activation and proteolytic activity of the Treponema pallidum metalloprotease, pallilysin","volume":"8","author":"Houston","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0735","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1128\/IAI.00643-15","article-title":"Conservation of the host-interacting proteins Tp0750 and pallilysin among treponemes and restriction of proteolytic capacity to Treponema pallidum","volume":"83","author":"Houston","year":"2015","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0740","doi-asserted-by":"crossref","first-page":"e0004110","DOI":"10.1371\/journal.pntd.0004110","article-title":"A retrospective study on genetic heterogeneity within Treponema strains: subpopulations are genetically distinct in a limited number of positions","volume":"9","author":"Cejkova","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0745","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ijmm.2014.04.007","article-title":"Syphilis-causing strains belong to separate SS14-like or Nichols-like groups as defined by multilocus analysis of 19 Treponema pallidum strains","volume":"304","author":"Nechvatal","year":"2014","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.vaccine.2016.03.111_bib0750","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.tim.2015.02.006","article-title":"Multipurpose prevention technologies: the future of HIV and STI protection","volume":"23","author":"Fernandez-Romero","year":"2015","journal-title":"Trends Microbiol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16301700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16301700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T07:03:47Z","timestamp":1717225427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16301700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":76,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0264410X16301700"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.03.111","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The global roadmap for advancing development of vaccines against sexually transmitted infections: Update and next steps","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.03.111","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 World Health Organization; licensee Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}